STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARVN
  4. [Form 4] Arvinas, Inc Insider Trading Activity

Arvinas Form 4: Routine 2,583-Share Sale by Chief Scientific Officer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arvinas, Inc. (ARVN) – Form 4 insider transaction filed 06/18/2025

Chief Scientific Officer Angela M. Cacace disclosed the sale of 2,583 common shares on 06/17/2025 at $7.49 per share. The company executed this sale automatically to satisfy tax-withholding obligations arising from the vesting and settlement of 50% of restricted stock units (RSUs) granted on 06/17/2024.

Post-transaction, the executive retains 154,248 shares held directly. No new options, warrants, or other derivative securities were reported, and the filing does not reference a Rule 10b5-1 trading plan.

Because the sale was issuer-directed and linked to tax withholding rather than discretionary portfolio rebalancing, it carries limited signaling value regarding the executive’s outlook. The relatively small size (≈1.7% of her holdings) further supports a neutral interpretation for investors.

Positive

  • Executive retains 154,248 shares, indicating continued alignment with shareholders.
  • Sale was automatic for tax withholding, reducing concern about negative insider sentiment.

Negative

  • Insider sale of 2,583 shares, albeit small, could be viewed cautiously by some investors.

Insights

TL;DR: Small, automatic tax-withholding sale by ARVN’s CSO; minimal impact on insider sentiment or share count.

The Form 4 shows a routine disposition tied to RSU vesting, not a discretionary sell decision. Only 2,583 shares (≈US$19k) were sold, leaving the officer with over 154k shares, so overall insider ownership remains strong. Because the transaction was executed by the issuer to cover payroll taxes, it is generally viewed as administrative and carries little predictive power for future stock performance. No derivative positions were exercised or altered, and no 10b5-1 plan was cited. Given the small size and non-discretionary nature, I consider the filing informational but not materially impactful to valuation or market sentiment.

Insider Cacace Angela M
Role Chief Scientific Officer
Sold 2,583 shs ($19K)
Type Security Shares Price Value
Sale Common Stock 2,583 $7.49 $19K
Holdings After Transaction: Common Stock — 154,248 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cacace Angela M
(Last) (First) (Middle)
C/O ARVINAS, INC.
5 SCIENCE PARK, 395 WINCHESTER AVE.
(Street)
NEW HAVEN CT 06511
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/17/2025 S 2,583(1) D $7.49 154,248 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 50% of the reporting person's restricted stock units (RSUs) granted on June 17, 2024.
Remarks:
/s/ Jared Freedberg, as attorney-in-fact for Angela M. Cacace 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Why did Angela M. Cacace sell shares of ARVN on 06/17/2025?

The sale was an automatic withholding transaction to cover taxes on vested RSUs granted 06/17/2024.

How many ARVN shares were sold in the Form 4 filing?

2,583 common shares were sold at $7.49 each.

How many Arvinas shares does the CSO still own after the transaction?

Angela M. Cacace now directly holds 154,248 shares of ARVN common stock.

Was the transaction made under a Rule 10b5-1 trading plan?

The filing does not indicate that a 10b5-1 plan governed this transaction.

Does the filing report any derivative security exercises?

No. No options or other derivatives were acquired or disposed of in this Form 4.